Search Results
10
Everything
Search Filters
Organization
Quantum BioPharma
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
March 31, 2025 07:00 ET
|
Quantum BioPharma
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final...
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025 04:30 ET
|
Quantum BioPharma
TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), has reported its financial and operational results...
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
March 27, 2025 07:00 ET
|
Quantum BioPharma
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Terry...
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
March 26, 2025 07:00 ET
|
Quantum BioPharma
Quantum Biopharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
March 20, 2025 07:30 ET
|
Quantum BioPharma
TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval...
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
February 26, 2025 07:30 ET
|
Quantum BioPharma
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
February 18, 2025 07:30 ET
|
Quantum BioPharma
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
February 11, 2025 07:30 ET
|
Quantum BioPharma
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
February 10, 2025 07:30 ET
|
Quantum BioPharma
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
February 06, 2025 07:30 ET
|
Quantum BioPharma
QUANTUM BIOPHARMA PARTNER CELLY NUTRITION RETAINS LEADING NEW YORK INVESTMENT BANK TO ADVISE ON CAPITAL RAISE AND POSSIBLE INITIAL PUBLIC OFFERING FOLLOWIN